Immunotherapy for the prevention and treatment of type 1 diabetes.
Int Rev Immunol
; 24(5-6): 307-26, 2005.
Article
em En
| MEDLINE
| ID: mdl-16318984
ABSTRACT
A major effort has been on-going to develop immunotherapies to prevent and/or treat type 1 diabetes (T1D). This autoimmune disease is characterized by the selective loss of the insulin-producing beta cells via the cumulative effects of autoantigen-specific CD4(+) and CD8(+) T cells, autoantibodies, and activated antigen-presenting cells. To be applicable in a clinical setting, immunotherapies must suppress established beta-cell autoimmunity. Preclinical studies and recent clinical findings suggest that antigen-specific and systemic-based strategies can be effective in this regard. However, either approach alone may not be sufficient to block the diabetogenic response and establish long-term protection in the clinic. In this review, we will discuss the importance of both strategies and how a combinatorial approach to treat T1D is appealing.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Diabetes Mellitus Tipo 1
/
Imunoterapia
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2005
Tipo de documento:
Article